Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06064422 · ClinicalTrials.gov registry record · NA

Adapting BA for Minimally Verbal Autistic Adults

A NA study of Depression and Autism Spectrum Disorder, sponsored by Rutgers, The State University of New Jersey.

Active
Registry status
NA
Development phase
15
Enrollment target
1
Study location

NCT06064422 is a NA study of Depression and Autism Spectrum Disorder that is active but no longer recruiting, run by Rutgers, The State University of New Jersey. The registered enrollment target is 15 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06064422, a NA study of Depression and Autism Spectrum Disorder, is active but no longer recruiting, sponsored by Rutgers, The State University of New Jersey.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
15 participants
Enrollment target
1
Study location

Study Summary

The present study aims to adapt and evaluate the feasibility of the BeatIt-2 behavioral activation intervention for people with intellectual disabilities and low mood to be implemented with minimally verbal autistic individuals.

Interventions

  • BEHAVIORAL BeatIt-MV

Study Locations (1)

New Jersey

  • Rutgers University - New Brunswick - Piscataway

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2023-11-01
Est. Completion 2025-08-30
Phase NA

What the Registry Record Tells You About NCT06064422

The ClinicalTrials.gov registry entry for NCT06064422 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 786-participant average among 679 other Depression trials with a reported enrollment target (98% lower). The listed sponsor is Rutgers, The State University of New Jersey, which has 413 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Depression appearing as the primary indexed condition, and to 1 intervention - of which BeatIt-MV is the first listed.

NCT06064422 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.

Frequently Asked Questions

What is clinical trial NCT06064422 about?

NCT06064422 is a clinical study titled "Adapting BA for Minimally Verbal Autistic Adults". The present study aims to adapt and evaluate the feasibility of the BeatIt-2 behavioral activation intervention for people with intellectual disabilities and low mood to be implemented with minimally verbal autistic individuals.

What is the current status of trial NCT06064422?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 15 participants. The study started on 2023-11-01. Estimated completion is 2025-08-30.

What conditions does trial NCT06064422 study?

This clinical trial studies the following conditions: Depression, Autism Spectrum Disorder, Autism, Autism Spectrum Disorder With Impaired Functional Language.

What interventions are being tested in trial NCT06064422?

The interventions under investigation include: BeatIt-MV (BEHAVIORAL).

Who is sponsoring clinical trial NCT06064422?

This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06064422 being conducted?

This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Depression

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.